| (USD) | Mar 2024 | Q/Q |
|---|---|---|
| Revenue | 5B | +7% |
| Gross Profit | 2.3B | - |
| Cost Of Revenue | 2.7B | +2% |
| Operating Income | 734MM | +67% |
| Operating Expenses | 1.6B | - |
| Net Income | 537MM | +91% |
| R&D | 299MM | +3% |
| G&A | 1.2B | -2% |
| Amortization | 366MM | +0% |
| Interest Expense | 125MM | +13% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced a global collaboration agreement to develop, manufacture and commercialize flow cytometry-based companion diagnostics (CDx) intended to help select the best treatment for patients with cancer and other diseases.
The Cooper Companies (COO) benefits from strength in its business segments. Its acquisitions are likely to drive the top line. A rise in selling, general and administrative expenses is, however, concerning.
The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has declared a quarterly dividend of $0.95 per common share, payable on September 30, 2024 to holders of record on September 9, 2024. The indicated annual dividend rate is $3.80 per share.
Becton Dickinson (BDX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
BDX vs. MMSI: Which Stock Is the Better Value Option?
Madison Investments, an investment advisor, released its “Madison Investors Fund” second-quarter 2024 investor letter. A copy of the letter can be downloaded here. In the second quarter, the fund (Class Y) fell by 1.03% compared to a 4.28% return for the S&P 500 index. YTD the fund returned 8.50% compared to a 15.29% return for […]
BD (BDX) faces a shortage of blood culture vials due to supplier issues. It is ramping up production and collaborating with the FDA to ensure patient care remains unaffected.
If you can count, you may find healthcare stocks focused on the aging population to be a compelling opportunity. What do I mean? When it comes to the senior care sector, the fundamental argument comes down to one word repeated three times: demographics, demographics, demographics. According to the U.S. Census Bureau, the “U.S. population age 65 and over grew nearly five times faster than the total population over the 100 years from 1920 to 2020.” Not only that, the older population reached 55.8
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today issued the following statement related to a U.S. FDA letter to health care providers regarding the supply of blood culture vials:
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has surpassed its Scope 1 and 2 science-based greenhouse gas (GHG) emissions reduction targets for FY 2023 by 5 percentage points and received approval for near and long-term science-based emissions reduction targets from the Science Based Target initiative (SBTi)[1]. This furthers the company's progress toward its goal to reach net zero GHG emissions across its value chain by FY 2050.